The therapeutic potential of carbon monoxide for inflammatory bowel disease.

Abstract

Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, are chronic, relapsing and remitting inflammatory disorders of the intestinal tract. Because the precise pathogenesis of IBD remains unclear, it is important to investigate the pathogenesis of IBD and to evaluate new anti-inflammatory strategies. Recent accumulating evidence has suggested that carbon monoxide (CO) may act as an endogenous defensive gaseous molecule to reduce inflammation and tissue injury in various organ injury models, including intestinal inflammation. Furthermore, exogenous CO administration at low concentrations is protective against intestinal inflammation. These data suggest that CO may be a novel therapeutic molecule in patients with IBD. In this review, we present what is currently known regarding the therapeutic potential of CO in intestinal inflammation.

• Authors: Tomohisa Takagi, Kazuhiko Uchiyama, Yuji Naito
• Journal: Digestion (Digestion) Vol. 91 Issue 1 Pg. 13-8 ( 2015) ISSN: 1421-9867 [Electronic] Switzerland
• PMID: 25632911 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: © 2015 S. Karger AG, Basel.

Chemical References

• Anti-Inflammatory Agents
• Gasotransmitters
• Carbon Monoxide

Topics

• Anti-Inflammatory Agents (therapeutic use)
• Carbon Monoxide (immunology, therapeutic use)
• Gasotransmitters (immunology, therapeutic use)
• Humans
• Inflammatory Bowel Diseases (drug therapy, immunology)